A novel whole blood gene expression signature for asthma, dermatitis, and rhinitis multimorbidity in children and adolescents.
asthma
atopic dermatitis
multimorbidity
rhinitis
transcriptomics
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
12
02
2020
revised:
25
03
2020
accepted:
30
03
2020
pubmed:
12
4
2020
medline:
15
5
2021
entrez:
12
4
2020
Statut:
ppublish
Résumé
Allergic diseases often occur in combination (multimorbidity). Human blood transcriptome studies have not addressed multimorbidity. Large-scale gene expression data were combined to retrieve biomarkers and signaling pathways to disentangle allergic multimorbidity phenotypes. Integrated transcriptomic analysis was conducted in 1233 participants with a discovery phase using gene expression data (Human Transcriptome Array 2.0) from whole blood of 786 children from three European birth cohorts (MeDALL), and a replication phase using RNA Sequencing data from an independent cohort (EVA-PR, n = 447). Allergic diseases (asthma, atopic dermatitis, rhinitis) were considered as single disease or multimorbidity (at least two diseases), and compared with no disease. Fifty genes were differentially expressed in allergic diseases. Thirty-two were not previously described in allergy. Eight genes were consistently overexpressed in all types of multimorbidity for asthma, dermatitis, and rhinitis (CLC, EMR4P, IL5RA, FRRS1, HRH4, SLC29A1, SIGLEC8, IL1RL1). All genes were replicated the in EVA-PR cohort. RT-qPCR validated the overexpression of selected genes. In MeDALL, 27 genes were differentially expressed in rhinitis alone, but none was significant for asthma or dermatitis alone. The multimorbidity signature was enriched in eosinophil-associated immune response and signal transduction. Protein-protein interaction network analysis identified IL5/JAK/STAT and IL33/ST2/IRAK/TRAF as key signaling pathways in multimorbid diseases. Synergistic effect of multimorbidity on gene expression levels was found. A signature of eight genes identifies multimorbidity for asthma, rhinitis, and dermatitis. Our results have clinical and mechanistic implications, and suggest that multimorbidity should be considered differently than allergic diseases occurring alone.
Sections du résumé
BACKGROUND
Allergic diseases often occur in combination (multimorbidity). Human blood transcriptome studies have not addressed multimorbidity. Large-scale gene expression data were combined to retrieve biomarkers and signaling pathways to disentangle allergic multimorbidity phenotypes.
METHODS
Integrated transcriptomic analysis was conducted in 1233 participants with a discovery phase using gene expression data (Human Transcriptome Array 2.0) from whole blood of 786 children from three European birth cohorts (MeDALL), and a replication phase using RNA Sequencing data from an independent cohort (EVA-PR, n = 447). Allergic diseases (asthma, atopic dermatitis, rhinitis) were considered as single disease or multimorbidity (at least two diseases), and compared with no disease.
RESULTS
Fifty genes were differentially expressed in allergic diseases. Thirty-two were not previously described in allergy. Eight genes were consistently overexpressed in all types of multimorbidity for asthma, dermatitis, and rhinitis (CLC, EMR4P, IL5RA, FRRS1, HRH4, SLC29A1, SIGLEC8, IL1RL1). All genes were replicated the in EVA-PR cohort. RT-qPCR validated the overexpression of selected genes. In MeDALL, 27 genes were differentially expressed in rhinitis alone, but none was significant for asthma or dermatitis alone. The multimorbidity signature was enriched in eosinophil-associated immune response and signal transduction. Protein-protein interaction network analysis identified IL5/JAK/STAT and IL33/ST2/IRAK/TRAF as key signaling pathways in multimorbid diseases. Synergistic effect of multimorbidity on gene expression levels was found.
CONCLUSION
A signature of eight genes identifies multimorbidity for asthma, rhinitis, and dermatitis. Our results have clinical and mechanistic implications, and suggest that multimorbidity should be considered differently than allergic diseases occurring alone.
Identifiants
pubmed: 32277847
doi: 10.1111/all.14314
pmc: PMC9302020
mid: NIHMS1821821
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3248-3260Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL117191
Pays : United States
Organisme : NIH HHS
ID : MD011764
Pays : United States
Organisme : NIMHD NIH HHS
ID : U54 MD007587
Pays : United States
Organisme : NIH HHS
ID : U54MD007587
Pays : United States
Organisme : NIMHD NIH HHS
ID : R01 MD011764
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL079966
Pays : United States
Informations de copyright
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Références
Methods. 2013 Sep 1;63(1):18-24
pubmed: 23563143
Eur Respir J. 2019 May 18;53(5):
pubmed: 30923181
Nat Genet. 2018 Jan;50(1):42-53
pubmed: 29273806
Eur J Pharmacol. 2011 Oct 1;668(1-2):1-5
pubmed: 21741967
Front Pharmacol. 2016 Dec 01;7:299
pubmed: 27990118
Endocrinology. 2007 Mar;148(3):1313-22
pubmed: 17170102
Pediatr Allergy Immunol. 2010 Nov;21(7):1052-8
pubmed: 20735756
Eur J Hum Genet. 2010 Jun;18(6):713-9
pubmed: 20087405
Nat Genet. 2017 Dec;49(12):1752-1757
pubmed: 29083406
Am J Respir Crit Care Med. 2017 May 15;195(10):1373-1383
pubmed: 27901618
Allergy. 2015 Sep;70(9):1062-78
pubmed: 25913421
Biostatistics. 2003 Apr;4(2):249-64
pubmed: 12925520
Inflammation. 2018 Jun;41(3):1021-1031
pubmed: 29460021
Genome Biol. 2014;15(12):550
pubmed: 25516281
Clin Exp Allergy. 2010 Apr;40(4):627-36
pubmed: 20082618
Allergy. 2008 Apr;63 Suppl 86:8-160
pubmed: 18331513
PLoS Med. 2014 Oct 21;11(10):e1001748
pubmed: 25335105
PLoS One. 2017 Jun 9;12(6):e0179125
pubmed: 28598986
Genome Biol. 2016 May 03;17:84
pubmed: 27142380
J Allergy Clin Immunol. 2017 Feb;139(2):388-399
pubmed: 28183433
N Engl J Med. 2008 Apr 3;358(14):1483-94
pubmed: 18385500
PLoS One. 2014 Jan 16;9(1):e78644
pubmed: 24454679
Molecules. 2018 Nov 09;23(11):
pubmed: 30424011
Int J Epidemiol. 2012 Aug;41(4):930-40
pubmed: 21471022
Lancet Respir Med. 2014 Feb;2(2):131-40
pubmed: 24503268
Lancet Respir Med. 2018 May;6(5):379-388
pubmed: 29496485
Am J Respir Crit Care Med. 1997 Apr;155(4):1413-8
pubmed: 9105087
BMC Med Genomics. 2015 Jan 13;8:1
pubmed: 25582225
Eur Respir J. 2018 Mar 8;51(3):
pubmed: 29519908
Eur J Pharmacol. 2015 Oct 5;764:149-156
pubmed: 26144372